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Full text: Politicians champion free trade for bringing an era of high and stable growth, although the evidence
supporting such claims is ambiguous. Studies that associate increases in trade with increases in gross domestic
product often leave open questions of causality: high growth, the result for instance of strong industrial policies,
typically leads to more trade. China and India's growth spurts preceded trade liberalisation. A study by UN
Development Programme showed little relation between trade liberalisation and growth.1 But trade liberalisation
is associated with growing inequality in most countries of the world (although there are other contributing
factors). Especially in conjunction with liberalisation in capital and financial markets, trade liberalisation has
brought unprecedented instability, even in countries with otherwise sound economic policies. Moreover, trade
liberalisation has deprived developing countries, which are heavily dependent on tariff s, of needed revenues.
The resulting combination of increases in poverty and social stress with decreased public spending is a
prescription for decreases in health status. Even a relatively short episode of malnutrition from a severe
downturn, of the kind that became all too common during the global fi nancial crisis of 1997-98, can have
lifelong consequences.2 But perhaps the most adverse consequences for health arise from provisions in trade
agreements that are designed to restrict access to generic medicines. These include the TRIPS (Agreement on
Trade-Related Aspects of Intellectual Property) provisions of the Uruguay Round Agreement of 1994 (as
discussed by Richard Smith and colleagues in a paper in this Series3) and the data exclusivity provisions that
have become a standard part of US4 and European5 bilateral trade agreements. The fundamental problem with
the intellectual property (patent) system is simple: it is based on restricting the use of knowledge.6 There is no
extra cost associated with an additional person gaining the benefi ts of knowledge. Restricting knowledge is
thus ineffi cient, but the patent system also grants (temporary) monopoly power, which gives rise to enormous
economic ineffi ciencies. In the USA, high prices make drugs particularly costly for people without insurance; in
the developing world, people cannot aff ord brand-name drugs, but might be able to aff ord generics. Generic
versions of fi rst-line AIDS drugs, for instance, have reduced the cost of treatment by 99% since 2000, from
US$10 000 to $130 per year.7 Advocates of intellectual property argue that such protection is necessary to
provide incentives for research. But drug companies spend far more money on advertising and marketing than
on research, far more on research for lifestyle drugs than on life-saving drugs, and almost no money on
diseases affl icting the poor countries, such as malaria. The reason is economics: companies direct their
research where the money is, regardless of the value to society. Poor people cannot pay for drugs, so there is
little research on their diseases, no matter what the costs to society. There is, moreover, little relation between
private rewards and social returns. A me-too drug can be highly profi table, even if its value to society is limited.
Similarly, companies raced to beat the human genome project to obtain patents on genes, such as BRCA1 and
BRCA2 in breast cancer. The value of these eff orts was minimal: the knowledge was produced a little sooner
than it would have been otherwise. But the cost to society was enormous, encompassing far more than the
wasted duplication of research. In the USA, the high price that Myriad Genetics, the holder of the BRCA
patents, will charge for genetic tests-over $2500-means that many women, who could otherwise have been
tested, discovered that they were at risk, and taken appropriate remediation, might die instead.8 Trade
advocates claim that in the World Trade Organization (WTO) there are built-in fl exibilities that allow access to
life-saving drugs through compulsory licensing. But these provisions were designed to make it diffi cult for
countries to issue such licences. If they wanted developing countries to have access to essential drugs, they
should have allowed automatic licences for all drugs except those that are not essential. When Thailand or
Brazil proposed to issue compulsory licences, enormous pressure came from the USA not to do so.9 To further
discourage governments from setting standards for granting patents that balance the social benefi ts and costs,
these trade agreements allow private parties to sue governments at the WTO. (In most other arenas, only
governments can bring action in the WTO.) The data-exclusivity provisions of the bilateral trade agreements
are, in some respects, even worse. They restrict the use of drug-company data (even when generated by
publicly funded research and/or published) to validate safety and effi cacy. Some of the trade agreements seem
to restrict use of bioequivalency. If a generic drug can be shown to be equivalent to a drug that has been
approved, why should it not be approved as well? Moreover, if a drug has been proven safe and eff ective, there
are ethical problems in testing an equivalent generic against placebo. Data exclusivity (with other related
provisions) can thus extend the eff ective life of a patent by as much as 10 years. But unlike patents, challenges
to claims of data exclusivity in court seem impossible, and there are worries that data exclusivity may even
prevent valid patent challenges from occurring before the period expires. These adverse eff ects of trade
liberalisation, and trade agreements on health are not inevitable. They are the result of how we have managed
trade-to enhance profi ts of the drug companies, not to enhance the health of those in the developing countries.
As I,6 and Richard Smith and other colleagues in another paper in this Series,10 have proposed, we can reform
our trade regimes and the way we fi nance and encourage research into drugs so as to improve health-and
even lower costs.6,10 Sidebar Published Online January 22, 2009 DOI:10.1016/S0140-6736(08)61772-9
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